These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34314919)

  • 1. Design, synthesis and biological evaluation of novel 5-(imidazolyl-methyl) thiazolidinediones as antidiabetic agents.
    Shakour N; Sahebkar A; Karimi G; Paseban M; Tasbandi A; Mosaffa F; Tayarani-Najaran Z; Ghodsi R; Hadizadeh F
    Bioorg Chem; 2021 Oct; 115():105162. PubMed ID: 34314919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, Synthesis, and Biological Evaluation of Thiazolidine-2,4-dione Conjugates as PPAR-γ Agonists.
    Nazreen S; Alam MS; Hamid H; Shahar Yar M; Dhulap A; Alam P; Pasha MA; Bano S; Alam MM; Haider S; Kharbanda C; Ali Y; Pillai K
    Arch Pharm (Weinheim); 2015 Jun; 348(6):421-32. PubMed ID: 25900064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, docking, in vitro and in vivo antidiabetic activity of pyrazole-based 2,4-thiazolidinedione derivatives as PPAR-γ modulators.
    Naim MJ; Alam O; Alam MJ; Shaquiquzzaman M; Alam MM; Naidu VGM
    Arch Pharm (Weinheim); 2018 Apr; 351(3-4):e1700223. PubMed ID: 29400412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, in silico molecular docking and biological evaluation of novel oxadiazole based thiazolidine-2,4-diones bis-heterocycles as PPAR-γ agonists.
    Nazreen S; Alam MS; Hamid H; Yar MS; Shafi S; Dhulap A; Alam P; Pasha MA; Bano S; Alam MM; Haider S; Ali Y; Kharbanda C; Pillai KK
    Eur J Med Chem; 2014 Nov; 87():175-85. PubMed ID: 25255433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiazolidine-2,4-diones derivatives as PPAR-γ agonists: synthesis, molecular docking, in vitro and in vivo antidiabetic activity with hepatotoxicity risk evaluation and effect on PPAR-γ gene expression.
    Nazreen S; Alam MS; Hamid H; Yar MS; Dhulap A; Alam P; Pasha MA; Bano S; Alam MM; Haider S; Kharbanda C; Ali Y; Pillai KK
    Bioorg Med Chem Lett; 2014 Jul; 24(14):3034-42. PubMed ID: 24890090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, biological evaluation and molecular docking studies of novel 3,5-disubstituted 2,4-thiazolidinediones derivatives.
    Ranjan Srivastava A; Bhatia R; Chawla P
    Bioorg Chem; 2019 Aug; 89():102993. PubMed ID: 31129500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and molecular docking of thiazolidinedione based benzene sulphonamide derivatives containing pyrazole core as potential anti-diabetic agents.
    Naim MJ; Alam O; Alam MJ; Hassan MQ; Siddiqui N; Naidu VGM; Alam MI
    Bioorg Chem; 2018 Feb; 76():98-112. PubMed ID: 29169079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated fragment-based drug design and virtual screening techniques for exploring the antidiabetic potential of thiazolidine-2,4-diones: Design, synthesis and in vivo studies.
    Gupta S; Baweja GS; Singh S; Irani M; Singh R; Asati V
    Eur J Med Chem; 2023 Dec; 261():115826. PubMed ID: 37793328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches.
    Hidalgo-Figueroa S; Ramírez-Espinosa JJ; Estrada-Soto S; Almanza-Pérez JC; Román-Ramos R; Alarcón-Aguilar FJ; Hernández-Rosado JV; Moreno-Díaz H; Díaz-Coutiño D; Navarrete-Vázquez G
    Chem Biol Drug Des; 2013 Apr; 81(4):474-83. PubMed ID: 23289972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models.
    Kanda S; Nakashima R; Takahashi K; Tanaka J; Ogawa J; Ogata T; Yachi M; Araki K; Ohsumi J
    J Pharmacol Sci; 2009 Oct; 111(2):155-66. PubMed ID: 19809220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, molecular docking and anti-diabetic evaluation of 2,4-thiazolidinedione based amide derivatives.
    Naim MJ; Alam MJ; Nawaz F; Naidu VGM; Aaghaz S; Sahu M; Siddiqui N; Alam O
    Bioorg Chem; 2017 Aug; 73():24-36. PubMed ID: 28582649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, in-Silico studies and biological evaluation of pyrimidine based thiazolidinedione derivatives as potential anti-diabetic agent.
    Amin S; Sheikh KA; Iqubal A; Ahmed Khan M; Shaquiquzzaman M; Tasneem S; Khanna S; Najmi AK; Akhter M; Haque A; Anwer T; Mumtaz Alam M
    Bioorg Chem; 2023 May; 134():106449. PubMed ID: 36889200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyrrolidinediones reduce the toxicity of thiazolidinediones and modify their anti-diabetic and anti-cancer properties.
    Saha S; Chan DS; Lee CY; Wong W; New LS; Chui WK; Yap CW; Chan EC; Ho HK
    Eur J Pharmacol; 2012 Dec; 697(1-3):13-23. PubMed ID: 23041271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, molecular docking, and in vivo antidiabetic evaluation of new benzylidene-2,4-thiazolidinediones as partial PPAR-γ agonists.
    Najmi A; Alam MS; Thangavel N; Taha MME; Meraya AM; Albratty M; Alhazmi HA; Ahsan W; Haque A; Azam F
    Sci Rep; 2023 Nov; 13(1):19869. PubMed ID: 37963936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, biological evaluation and molecular modeling studies of arylidene-thiazolidinediones with potential hypoglycemic and hypolipidemic activities.
    da Costa Leite LF; Veras Mourão RH; de Lima Mdo C; Galdino SL; Hernandes MZ; de Assis Rocha Neves F; Vidal S; Barbe J; da Rocha Pitta I
    Eur J Med Chem; 2007 Oct; 42(10):1263-71. PubMed ID: 17448573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and glucose uptake activity of some novel glitazones.
    Kar K; Krithika U; Mithuna ; Basu P; Santhosh Kumar S; Reji A; Prashantha Kumar BR
    Bioorg Chem; 2014 Oct; 56():27-33. PubMed ID: 24927033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
    Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
    Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of new dual PPARγ-GPR40 agonists with robust antidiabetic activity: Design, synthesis and in combo drug evaluation.
    Hidalgo-Figueroa S; Navarrete-Vázquez G; Estrada-Soto S; Giles-Rivas D; Alarcón-Aguilar FJ; León-Rivera I; Giacoman-Martínez A; Miranda Pérez E; Almanza-Pérez JC
    Biomed Pharmacother; 2017 Jun; 90():53-61. PubMed ID: 28342366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biocatalytic one pot three component approach: Facile synthesis, characterization, molecular modelling and hypoglycemic studies of new thiazolidinedione festooned quinoline analogues catalyzed by alkaline protease from Aspergillus niger.
    Angajala G; Aruna V; Pavan P; Guruprasad Reddy P
    Bioorg Chem; 2022 Feb; 119():105533. PubMed ID: 34902647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hybrid drug combination: Anti-diabetic treatment of type 2 diabetic Wistar rats with combination of ellagic acid and pioglitazone.
    Nankar RP; Doble M
    Phytomedicine; 2017 Dec; 37():4-9. PubMed ID: 29103827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.